| dc.contributor.author | Halvorsen, Joar Øveraas | |
| dc.contributor.author | Naudet, Florian | |
| dc.contributor.author | Cristea, Ioana A. | |
| dc.date.accessioned | 2022-09-09T11:14:37Z | |
| dc.date.available | 2022-09-09T11:14:37Z | |
| dc.date.created | 2021-10-11T19:10:01Z | |
| dc.date.issued | 2021 | |
| dc.identifier.citation | Nature Medicine. 2021, 27 (10), 1689-1690. | en_US |
| dc.identifier.issn | 1078-8956 | |
| dc.identifier.uri | https://hdl.handle.net/11250/3016871 | |
| dc.description.abstract | To represent a treatment breakthrough, 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder (PTSD) should be evaluated against first-line psychological interventions or for prespecified patient subgroups that do not improve after such interventions. | en_US |
| dc.language.iso | eng | en_US |
| dc.publisher | Nature Research | en_US |
| dc.title | Challenges with benchmarking of MDMA-assisted psychotherapy | en_US |
| dc.type | Peer reviewed | en_US |
| dc.type | Journal article | en_US |
| dc.description.version | publishedVersion | en_US |
| dc.rights.holder | This version of the article will not be available due to copyright restrictions by Nature Research | en_US |
| dc.source.pagenumber | 1689-1690 | en_US |
| dc.source.volume | 27 | en_US |
| dc.source.journal | Nature Medicine | en_US |
| dc.source.issue | 10 | en_US |
| dc.identifier.doi | 10.1038/s41591-021-01525-0 | |
| dc.identifier.cristin | 1945022 | |
| cristin.ispublished | true | |
| cristin.fulltext | original | |
| cristin.qualitycode | 2 | |
